Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo

Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo

Cisplatin is a commonly used chemotherapeutic drug for treatment of oral carcinoma, and combinatorial effects are expected to exert greater therapeutic efficacy compared with monotherapy. Poly(ADP-ribosyl)ation is reported to be involved in a variety of cellular processes, such as DNA repair, cell d...

Full description

Bibliographic Details
Main Authors: Masaaki Yasukawa, Hisako Fujihara, Hiroaki Fujimori, Koji Kawaguchi, Hiroyuki Yamada, Ryoko Nakayama, Nanami Yamamoto, Yuta Kishi, Yoshiki Hamada, Mitsuko Masutani
Format: Article
Language:English
Published: MDPI AG 2016-02-01
Series:International Journal of Molecular Sciences
Subjects:
PARP inhibitor
oral cancer
xenografted tumor
cisplatin
Online Access:http://www.mdpi.com/1422-0067/17/3/272

Internet

http://www.mdpi.com/1422-0067/17/3/272

Similar Items